Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.

中文翻译：

---

评估针对癌症干细胞的治疗功效：新范式带来的新挑战。

当前的抗癌药功效度量反映了大细胞杀伤，并且不适合检测针对维持肿瘤生长的癌症干细胞（CSC）的活性。CSC范式需要重新审查用于评估抗癌疗法的临床疗效的方法，以及在临床前药物开发过程中采用的策略。